Breaking News Instant updates and real-time market news.

GNBT

Generex

$0.00 /

+ (+0.00%)

09:00
04/27/20
04/27
09:00
04/27/20
09:00

Generex publishes response to Congressional letter on COVID-19

Generex Biotechnology published a response to the April 20th letter from Congressional members to HHS Secretary Alex Azar and FDA Commissioner Stephan Hahn, MD wherein they call for an accelerated development path for a vaccine to the SARS-CoV-2 coronavirus pandemic using viral challenge studies. Generex President & CEO Joseph Moscato presents a corporate response to the idea of conducting challenge studies with this coronavirus and provides details of how Generex is responding to this global emergency by offering a safer solution with the Ii-Key vaccine technology. The company said, "Upon reading the letter that was sent last week by Congress to Secretary Azar and Commissioner Hahn, the Generex management team and I were sufficiently alarmed to publish this response to the proposal that vaccine developers intentionally infect healthy young people with the deadly SARS-CoV-2 coronavirus to speed up vaccine development. While we wholeheartedly support the proposition that we accelerate the vaccine development process, especially in this time of emergency pandemic response, the idea of conducting a challenge study using such a new and incompletely understood virus that has wreaked devastation around the globe is incomprehensible when there are safer and better ways available to us right now. Plus, it is not just the virus that is dangerous. There are serious potential risks of vaccination as well, especially with whole virus and large subunit vaccines that are known to cause off-target effects. Anyone who wants to consider volunteering for a COVID-19 vaccine challenge study should read the article about a vaccine that was developed for the previous SARS outbreak that was published in the American Chemical Society Journal of Infectious Diseases in 2016. That article reports the results of a viral challenge study in monkeys using an inactivated SARS-CoV-1 vaccine. When the monkeys were vaccinated, their immune systems generated antibodies against the whole virus, a normal immune response to viral infection; then they infected the monkeys with the SARS virus. While some antibodies conferred protection from the viral challenge, other antibodies caused serious lung damage in the monkeys and enhanced COVID disease resulting in the honeycomb lung that we see in patients who have died during the current SARS-CoV-2 outbreak. So, anyone who enrolls in a viral challenge study risks not only a deadly disease, but also worsening of the disease because the non-specific vaccine may produce unwanted immune system overreactions. At Generex, we understand the risks of developing a vaccine for this coronavirus, because for the last two months the team at Generex has been working around the clock to advance the development of a new COVID-19 vaccine using our targeted Ii-Key vaccine technology to specifically target the immune system against the SARS-CoV-2 virus. We are moving forward with a rational scientific approach and a conservative regulatory strategy that first and foremost ensures the safety of people who volunteer to participate in our clinical research trials of an Ii-Key-SARS-CoV-2 peptide vaccine. With our development partners, we have used computational algorithms to identify specific antigenic peptides from the viral spike, envelope, and membrane proteins that are highly conserved across other deadly coronaviruses like SARS-1 and MERS, have no human sequences that could cause autoimmune reactions, and contain amino acid sequences most likely to produce a neutralizing antibodies based on historical data and computational analyses. We are manufacturing these peptides with the Ii-Key and will be screening them against blood samples from patients who have recovered from COVID-19. The blood from previously infected individuals contains T-Cells and antibodies that have actually worked to neutralize the coronavirus infection so the patients could recover from COVID-19. This standard protocol, which has been developed over the years by the NuGenerex Immuno-Oncology team, enables us to identify specific coronavirus peptide epitopes that produce neutralizing, rather than off-target antibodies, and activate appropriate T-helper cell responses through the Ii-Key rather than the potentially dangerous TH2 responses that are part of the cytokine storm. In this fashion, we can not only select the proper, specific epitopes for a peptide vaccine, but we also test the specificity of the immune response generated by our Ii-Key-SARS-CoV-2 peptide vaccine in a 100% safe "Ex-Vivo" human clinical trial before we proceed to the clinic. Generex has had numerous discussions with U.S. government agencies, including HHS, FDA, and BARDA, the government funding agency that has requested that we submit a contract proposal to provide them with details of our Ii-Key-SARS-CoV-2 peptide vaccine development program. Today, we are submitting that proposal, written and compiled by the Generex COVID-19 task force with detailed plans and budgets from our scientific and clinical team, our contract manufacturing partners, clinical laboratories, preeminent infectious disease research laboratories, a major clinical research organization, regulatory consultants, key opinion leaders in vaccine development and infectious disease, and clinical research sites to conduct the safety and efficacy trials required for FDA fast track approval. We have also agreed to partner with a major corporation that is developing a vaccine adjuvant formulation that we plan to evaluate in our proposed clinical trials. Again, our planned clinical trials are 100% focused on patient safety with interim reviews by an independent data safety monitoring board or DSMB that will evaluate the data not only for safety but also for futility if the vaccine does not induce the appropriate immune responses necessary to kill the virus. With this ongoing review of clinical safety and futility, our plan de-risks our vaccine development program for patients, the medical community, the government, and our investors, with patient safety being of the utmost importance."

GNBT Generex
$0.00 /

+ (+0.00%)

06/26/19
Generex's Olaregen receives APMA 'seal of approval' for Excellagen Matrix

TODAY'S FREE FLY STORIES

Upgrade
Roth Capital reverts back to Buy on Vaalco Energy after meeting new CEO » 11:49
04/13/21
04/13
11:49
04/13/21
11:49
EGY

Vaalco Energy

$2.20 /

-0.04 (-1.79%)

Roth Capital analyst John…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EGY Vaalco Energy
$2.20 /

-0.04 (-1.79%)

EGY Vaalco Energy
$2.20 /

-0.04 (-1.79%)

11:44 Today Roth Capital
Vaalco Energy upgraded to Buy from Neutral at Roth Capital
04/12/21 Roth Capital
Vaalco Energy downgraded to Neutral from Buy at Roth Capital
03/24/21 Roth Capital
Vaalco Energy initiated with a Buy at Roth Capital
Hot Stocks
LVMH says 'well-equipped to build upon the hoped-for recovery' » 11:48
04/13/21
04/13
11:48
04/13/21
11:48
LVMUY

LVMH

$140.99 /

+0.23 (+0.16%)

The company said,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

04/07/21 Deutsche Bank
LVMH price target raised to EUR 495 from EUR 440 at Deutsche Bank
03/30/21 UBS
LVMH price target raised to EUR 640 from EUR 623 at UBS
03/29/21 Morgan Stanley
LVMH price target raised to EUR 625 from EUR 600 at Morgan Stanley
03/15/21 UBS
LVMH price target raised to EUR 623 from EUR 604 at UBS
LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

Earnings
LVMH reports Q1 revenue EUR 13.96B, consensus EUR 12.7B » 11:47
04/13/21
04/13
11:47
04/13/21
11:47
LVMUY

LVMH

$140.99 /

+0.23 (+0.16%)

Organic revenue grew 8%…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

04/07/21 Deutsche Bank
LVMH price target raised to EUR 495 from EUR 440 at Deutsche Bank
03/30/21 UBS
LVMH price target raised to EUR 640 from EUR 623 at UBS
03/29/21 Morgan Stanley
LVMH price target raised to EUR 625 from EUR 600 at Morgan Stanley
03/15/21 UBS
LVMH price target raised to EUR 623 from EUR 604 at UBS
LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

LVMUY LVMH
$140.99 /

+0.23 (+0.16%)

Recommendations
Trulieve Cannabis price target raised to C$90 from C$87 at Canaccord » 11:46
04/13/21
04/13
11:46
04/13/21
11:46
TCNNF

Trulieve Cannabis

$39.61 /

-1.39 (-3.39%)

Canaccord analyst Derek…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TCNNF Trulieve Cannabis
$39.61 /

-1.39 (-3.39%)

TCNNF Trulieve Cannabis
$39.61 /

-1.39 (-3.39%)

03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
03/25/21 Stifel
Trulieve Cannabis price target raised to C$118 from C$107 at Stifel
03/24/21 Canaccord
Trulieve Cannabis price target raised to C$87 from C$75 at Canaccord
03/24/21 Cantor Fitzgerald
Trulieve Cannabis price target raised to $84 from $70 at Cantor Fitzgerald
TCNNF Trulieve Cannabis
$39.61 /

-1.39 (-3.39%)

TCNNF Trulieve Cannabis
$39.61 /

-1.39 (-3.39%)

TCNNF Trulieve Cannabis
$39.61 /

-1.39 (-3.39%)

Recommendations
Filo Mining price target raised to C$5 from C$2.50 at Canaccord » 11:46
04/13/21
04/13
11:46
04/13/21
11:46
FLMMF

Filo Mining

$2.68 /

-0.2168 (-7.48%)

Canaccord analyst Dalton…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FLMMF Filo Mining
$2.68 /

-0.2168 (-7.48%)

01/13/21 National Bank
Filo Mining upgraded to Outperform from Sector Perform at National Bank
08/07/20 BMO Capital
Filo Mining initiated with an Outperform at BMO Capital
Options
JetBlue call volume above normal and directionally bullish » 11:45
04/13/21
04/13
11:45
04/13/21
11:45
JBLU

JetBlue

$20.46 /

-0.035 (-0.17%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JBLU JetBlue
$20.46 /

-0.035 (-0.17%)

JBLU JetBlue
$20.46 /

-0.035 (-0.17%)

09:55 Today
Fly Intel: Top five analyst upgrades
07:01 Today Susquehanna
JetBlue upgraded to Positive at Susquehanna
05:55 Today Susquehanna
JetBlue upgraded to Positive from Neutral at Susquehanna
04/06/21 Morgan Stanley
JetBlue price target raised to $30 from $18 at Morgan Stanley
JBLU JetBlue
$20.46 /

-0.035 (-0.17%)

  • 02
    Dec
JBLU JetBlue
$20.46 /

-0.035 (-0.17%)

JBLU JetBlue
$20.46 /

-0.035 (-0.17%)

JBLU JetBlue
$20.46 /

-0.035 (-0.17%)

General news
FX Action: USD-JPY » 11:45
04/13/21
04/13
11:45
04/13/21
11:45
$ECON

Economic Data

/

+

FX Action: USD-JPY topped…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
    General news
    European Fixed Income Summary: » 11:45
    04/13/21
    04/13
    11:45
    04/13/21
    11:45
    $ECON

    Economic Data

    /

    +

    European Fixed Income…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return in 9 minutes

    Get Free Trial

    ShowHide Related Items >><<
      Conference/Events
      Hawaiian Airlines executives participate in a virtual event » 11:45
      04/13/21
      04/13
      11:45
      04/13/21
      11:45
      HA

      Hawaiian Holdings

      $25.14 /

      -0.39 (-1.53%)

      Stanford Institute for…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      HA Hawaiian Holdings
      $25.14 /

      -0.39 (-1.53%)

      HA Hawaiian Holdings
      $25.14 /

      -0.39 (-1.53%)

      03/22/21 Stifel
      Hawaiian Holdings price target raised to $27 from $19 at Stifel
      03/16/21 Goldman Sachs
      Hawaiian Holdings price target raised to $14 from $7 at Goldman Sachs
      03/05/21 Wolfe Research
      Wolfe upgrades Hawaiian Holdings to Peer Perform on tourism 'snap up' potential
      03/05/21 Wolfe Research
      Hawaiian Holdings upgraded to Peer Perform from Underperform at Wolfe Research
      HA Hawaiian Holdings
      $25.14 /

      -0.39 (-1.53%)

      HA Hawaiian Holdings
      $25.14 /

      -0.39 (-1.53%)

      HA Hawaiian Holdings
      $25.14 /

      -0.39 (-1.53%)

      Conference/Events
      Federal Reserve Bank of Kansas City president participates in virtual event » 11:45
      04/13/21
      04/13
      11:45
      04/13/21
      11:45

      Kansas City Federal…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      Upgrade
      Vaalco Energy upgraded to Buy from Neutral at Roth Capital » 11:44
      04/13/21
      04/13
      11:44
      04/13/21
      11:44
      EGY

      Vaalco Energy

      $2.20 /

      -0.04 (-1.79%)

      Roth Capital analyst John…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
      EGY Vaalco Energy
      $2.20 /

      -0.04 (-1.79%)

      EGY Vaalco Energy
      $2.20 /

      -0.04 (-1.79%)

      04/12/21 Roth Capital
      Vaalco Energy downgraded to Neutral from Buy at Roth Capital
      03/24/21 Roth Capital
      Vaalco Energy initiated with a Buy at Roth Capital
      Recommendations
      Fortuna Silver Mines price target raised to C$12.50 from C$12.25 at BMO Capital » 11:43
      04/13/21
      04/13
      11:43
      04/13/21
      11:43
      FSM

      Fortuna Silver Mines

      $7.48 /

      +0.315 (+4.40%)

      BMO Capital analyst Ryan…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      FSM Fortuna Silver Mines
      $7.48 /

      +0.315 (+4.40%)

      FSM Fortuna Silver Mines
      $7.48 /

      +0.315 (+4.40%)

      03/29/21 BMO Capital
      Fortuna Silver Mines price target lowered to $12.75 from $13 at BMO Capital
      03/11/21 BMO Capital
      Fortuna Silver Mines price target raised to C$13 from C$12 at BMO Capital
      02/08/21 CIBC
      Fortuna Silver Mines price target lowered to C$11.25 from C$11.50 at CIBC
      02/02/21 National Bank
      Fortuna Silver Mines price target raised to C$13.50 from C$13 at National Bank
      FSM Fortuna Silver Mines
      $7.48 /

      +0.315 (+4.40%)

      FSM Fortuna Silver Mines
      $7.48 /

      +0.315 (+4.40%)

      FSM Fortuna Silver Mines
      $7.48 /

      +0.315 (+4.40%)

      FSM Fortuna Silver Mines
      $7.48 /

      +0.315 (+4.40%)

      Conference/Events
      Global Ship Lease management to meet virtually with Jefferies » 11:42
      04/13/21
      04/13
      11:42
      04/13/21
      11:42
      GSL

      Global Ship Lease

      $12.75 /

      -0.14 (-1.09%)

      Virtual Meeting to be…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
      GSL Global Ship Lease
      $12.75 /

      -0.14 (-1.09%)

      GSL Global Ship Lease
      $12.75 /

      -0.14 (-1.09%)

      02/12/21
      Fly Intel: Top five analyst initiations
      02/12/21 Jefferies
      Global Ship Lease initiated with a Buy at Jefferies
      01/15/21 B. Riley Securities
      Global Ship Lease price target raised to $20 from $16 at B. Riley Securities
      01/06/21 B. Riley Securities
      Global Ship Lease price target raised to $16 from $12 at B. Riley Securities
      GSL Global Ship Lease
      $12.75 /

      -0.14 (-1.09%)

      • 09
        Apr
      • 22
        Jan
      GSL Global Ship Lease
      $12.75 /

      -0.14 (-1.09%)

      Initiation
      Daqo New Energy initiated with a Sell at GLJ Research » 11:39
      04/13/21
      04/13
      11:39
      04/13/21
      11:39
      DQ

      Daqo New Energy

      $66.50 /

      -0.54 (-0.81%)

      GLJ Research analyst…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      DQ Daqo New Energy
      $66.50 /

      -0.54 (-0.81%)

      DQ Daqo New Energy
      $66.50 /

      -0.54 (-0.81%)

      03/10/21 Roth Capital
      Daqo New Energy price target lowered to $97 from $115 at Roth Capital
      03/02/21 Roth Capital
      Daqo New Energy price target raised to $115 from $105 at Roth Capital
      02/08/21 Roth Capital
      Bill could be 'meaningful positive' for solar stocks, says Roth Capital
      01/26/21 Roth Capital
      Daqo New Energy price target raised to $100 from $40 at Roth Capital
      DQ Daqo New Energy
      $66.50 /

      -0.54 (-0.81%)

      DQ Daqo New Energy
      $66.50 /

      -0.54 (-0.81%)

      DQ Daqo New Energy
      $66.50 /

      -0.54 (-0.81%)

      DQ Daqo New Energy
      $66.50 /

      -0.54 (-0.81%)

      Hot Stocks
      MoneyGram announces partnership with Sigue Corporation » 11:34
      04/13/21
      04/13
      11:34
      04/13/21
      11:34
      MGI

      MoneyGram

      $6.46 /

      -0.01 (-0.15%)

      MoneyGram International…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
      MGI MoneyGram
      $6.46 /

      -0.01 (-0.15%)

      MGI MoneyGram
      $6.46 /

      -0.01 (-0.15%)

      02/25/21 Barclays
      MoneyGram price target raised to $6 from $4.50 at Barclays
      01/19/21 DA Davidson
      DA Davidson doesn't see Walmart adding Western Union to hurt Euronet materially
      01/11/21 Northland
      MoneyGram upgraded to Outperform from Market Perform at Northland
      08/03/20 Evercore ISI
      MoneyGram upgraded to In Line from Underperform at Evercore ISI
      MGI MoneyGram
      $6.46 /

      -0.01 (-0.15%)

      MGI MoneyGram
      $6.46 /

      -0.01 (-0.15%)

      MGI MoneyGram
      $6.46 /

      -0.01 (-0.15%)

      MGI MoneyGram
      $6.46 /

      -0.01 (-0.15%)

      Recommendations
      Novocure price target raised to $215 from $135 at Wells Fargo » 11:34
      04/13/21
      04/13
      11:34
      04/13/21
      11:34
      NVCR

      Novocure

      $183.50 /

      +51.89 (+39.43%)

      Wells Fargo analyst…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      NVCR Novocure
      $183.50 /

      +51.89 (+39.43%)

      NVCR Novocure
      $183.50 /

      +51.89 (+39.43%)

      10:48 Today Guggenheim
      Zai Lab price target raised to $250 from $165 at Guggenheim
      09:26 Today Piper Sandler
      DMC review 'clear positive' for Novocure, says Piper Sandler
      03/01/21 Mizuho
      Novocure price target raised to $175 from $150 at Mizuho
      02/25/21 Piper Sandler
      'Overreaction to downside' in Novocure a buying opportunity, says Piper Sandler
      NVCR Novocure
      $183.50 /

      +51.89 (+39.43%)

      NVCR Novocure
      $183.50 /

      +51.89 (+39.43%)

      Periodicals
      GM shortens expected downtime at Tennessee plant, CNBC reports » 11:28
      04/13/21
      04/13
      11:28
      04/13/21
      11:28
      GM

      General Motors

      $58.37 /

      -1.295 (-2.17%)

      General Motors is…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
      GM General Motors
      $58.37 /

      -1.295 (-2.17%)

      GM General Motors
      $58.37 /

      -1.295 (-2.17%)

      04/05/21
      Fly Intel: Top five analyst initiations
      04/05/21 Wells Fargo
      General Motors initiated with an Overweight at Wells Fargo
      03/29/21 Jefferies
      General Motors price target raised to $62 from $50 at Jefferies
      03/24/21 Morgan Stanley
      American Axle downgraded to Underweight on ICE phase out risk at Morgan Stanley
      GM General Motors
      $58.37 /

      -1.295 (-2.17%)

      GM General Motors
      $58.37 /

      -1.295 (-2.17%)

      GM General Motors
      $58.37 /

      -1.295 (-2.17%)

      GM General Motors
      $58.37 /

      -1.295 (-2.17%)

      Options
      iQiyi call volume above normal and directionally bullish » 11:25
      04/13/21
      04/13
      11:25
      04/13/21
      11:25
      IQ

      iQIYI

      $16.69 /

      +0.515 (+3.18%)

      Bullish option flow…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      IQ iQIYI
      $16.69 /

      +0.515 (+3.18%)

      IQ iQIYI
      $16.69 /

      +0.515 (+3.18%)

      02/22/21 KeyBanc
      iQIYI upgraded to Overweight from Sector Weight at KeyBanc
      02/18/21
      Fly Intel: Top five analyst downgrades
      02/18/21 JPMorgan
      iQIYI downgraded to Underweight from Neutral at JPMorgan
      01/19/21 UBS
      iQIYI downgraded to Neutral from Buy at UBS
      IQ iQIYI
      $16.69 /

      +0.515 (+3.18%)

      • 17
        Dec
      IQ iQIYI
      $16.69 /

      +0.515 (+3.18%)

      IQ iQIYI
      $16.69 /

      +0.515 (+3.18%)

      IQ iQIYI
      $16.69 /

      +0.515 (+3.18%)

      Conference/Events
      Cowen Washington strategist to hold analyst/industry conference call » 11:25
      04/13/21
      04/13
      11:25
      04/13/21
      11:25

      Washington Strategist…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      Periodicals
      KKR planning to outbid CVC for Toshiba with offer in excess of $20B, FT reports » 11:23
      04/13/21
      04/13
      11:23
      04/13/21
      11:23
      TOSYY

      Toshiba

      $20.85 /

      +0.03 (+0.14%)

      , KKR

      KKR

      $52.09 /

      +0.08 (+0.15%)

      KKR (KKR) is planning to…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
      TOSYY Toshiba
      $20.85 /

      +0.03 (+0.14%)

      KKR KKR
      $52.09 /

      +0.08 (+0.15%)

      TOSYY Toshiba
      $20.85 /

      +0.03 (+0.14%)

      03/19/21 SMBC Nikko
      Toshiba upgraded to Outperform from Neutral at SMBC Nikko
      02/19/21 Citi
      Toshiba resumed with a Neutral at Citi
      04/22/20 UBS
      Toshiba downgraded to Neutral from Buy at UBS
      KKR KKR
      $52.09 /

      +0.08 (+0.15%)

      04/09/21 DA Davidson
      Box price target lowered to $22 from $25 at DA Davidson
      04/09/21 William Blair
      KKR investment 'strong vote of confidence' in Box, says William Blair
      04/09/21 William Blair
      KKR investment 'strong vote of confidence' in Box, says William Blair
      04/07/21 Seaport Global
      Seaport downgrades Sempra Energy to Neutral after 'good, not great' SIP deal
      KKR KKR
      $52.09 /

      +0.08 (+0.15%)

      • 11
        Nov
      TOSYY Toshiba
      $20.85 /

      +0.03 (+0.14%)

      KKR KKR
      $52.09 /

      +0.08 (+0.15%)

      TOSYY Toshiba
      $20.85 /

      +0.03 (+0.14%)

      KKR KKR
      $52.09 /

      +0.08 (+0.15%)

      Recommendations
      Stelco Holdings price target raised to C$34 from C$29 at RBC Capital » 11:20
      04/13/21
      04/13
      11:20
      04/13/21
      11:20
      STZHF

      Stelco Holdings

      $23.05 /

      -0.23 (-0.99%)

      RBC Capital analyst…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return in 9 minutes

      Get Free Trial

      ShowHide Related Items >><<
      STZHF Stelco Holdings
      $23.05 /

      -0.23 (-0.99%)

      03/31/21 Scotiabank
      Stelco Holdings price target raised to C$32 from C$30 at Scotiabank
      02/24/21 RBC Capital
      Stelco Holdings upgraded to Outperform from Sector Perform at RBC Capital
      02/22/21 Exane BNP Paribas
      Stelco Holdings upgraded to Outperform from Neutral at Exane BNP Paribas
      02/03/21 Credit Suisse
      Stelco Holdings upgraded to Outperform from Neutral at Credit Suisse
      General news
      Treasury announced an $80 B set of 4- and 8-week bill auctions for Thursday » 11:20
      04/13/21
      04/13
      11:20
      04/13/21
      11:20
      $ECON

      Economic Data

      /

      +

      Treasury announced an $80…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
        Recommendations
        Ascot Resources price target lowered to C$1.85 from C$2 at Desjardins » 11:19
        04/13/21
        04/13
        11:19
        04/13/21
        11:19
        AOTVF

        Ascot Resources

        /

        +

        Desjardins analyst David…

        Story temporarily locked.
        To read stories as they happen please subscribe, Login above, or return in 9 minutes

        Get Free Trial

        ShowHide Related Items >><<
        AOTVF Ascot Resources
        /

        +

        AOTVF Ascot Resources
        /

        +

        12/11/20 Raymond James
        Ascot Resources price target raised to C$2 from C$1.75 at Raymond James
        09/25/20 Raymond James
        Ascot Resources initiated with a Strong Buy at Raymond James
        04/29/20 Roth Capital
        Roth Capital bullish on Ascot Resources, initiates with a Buy
        04/29/20 Roth Capital
        Ascot Resources initiated with a Buy at Roth Capital
        Recommendations
        Rigel results in severe COVID-19 trial 'pretty dramatic,' says Piper Sandler » 11:19
        04/13/21
        04/13
        11:19
        04/13/21
        11:19
        RIGL

        Rigel Pharmaceuticals

        $3.50 /

        +0.405 (+13.09%)

        After Rigel…

        Story temporarily locked.
        To read stories as they happen please subscribe, Login above, or return tomorrow

        Get Free Trial

        ShowHide Related Items >><<
        RIGL Rigel Pharmaceuticals
        $3.50 /

        +0.405 (+13.09%)

        RIGL Rigel Pharmaceuticals
        $3.50 /

        +0.405 (+13.09%)

        02/18/21 H.C. Wainwright
        Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
        02/18/21 Piper Sandler
        Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
        11/09/20
        Fly Intel: Top five analyst downgrades
        11/09/20 JPMorgan
        Rigel Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
        RIGL Rigel Pharmaceuticals
        $3.50 /

        +0.405 (+13.09%)

        RIGL Rigel Pharmaceuticals
        $3.50 /

        +0.405 (+13.09%)

        Conference/Events
        Immunocore participates in a conference call with JPMorgan » 11:19
        04/13/21
        04/13
        11:19
        04/13/21
        11:19
        IMCR

        Immunocore

        $34.25 /

        +2.03 (+6.30%)

        SMid Cap Biotech Analyst…

        Story temporarily locked.
        To read stories as they happen please subscribe, Login above, or return in 9 minutes

        Get Free Trial

        ShowHide Related Items >><<
        IMCR Immunocore
        $34.25 /

        +2.03 (+6.30%)

        IMCR Immunocore
        $34.25 /

        +2.03 (+6.30%)

        03/02/21 Jefferies
        Immunocore initiated with a Buy at Jefferies
        03/02/21 JPMorgan
        Immunocore initiated with an Overweight at JPMorgan
        03/02/21 Goldman Sachs
        Immunocore initiated with a Neutral at Goldman Sachs
        IMCR Immunocore
        $34.25 /

        +2.03 (+6.30%)

        • 05
          Feb
        IMCR Immunocore
        $34.25 /

        +2.03 (+6.30%)

        Get Full Fly Access

        Breaking market intelligence sent straight to you
        Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
        Up-to-date information on important industry events
        Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
        News focused on the companies in your portfolio
        Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.